FIELD: medicine; hematology.
SUBSTANCE: invention can be used to determine the prognosis of relapse in patients with acute myeloid leukemia (AML) based on the results of the assessment of minimal residual disease (MRD) in the post-induction phase of treatment after the 1st checkpoint — in the period from the 35th to the 42nd day after the 1st course of induction chemotherapy and the 2nd checkpoint — in the period from the 70th to the 84th day after the 2nd course of induction chemotherapy. Residual tumor cells are detected by multicolor flow cytometry in patients with acute myeloid leukemia at two control points. At the first stage, all CD34-positive cells are isolated and sequentially analyzed for the expression of all antigens, isolating all CD34-positive cells normally present in healthy donors. At the second stage, all CD117-positive cells are isolated and sequentially analyzed for the expression of all antigens, isolating all CD117-positive cells normally present in healthy donors. At the third stage, all CD117-CD34-cells are isolated and sequentially analyzed for the expression of all antigens, isolating all CD117-CD34 cells normally present in healthy donors. When diagnosing the presence of MRD after the 1st course and/or the 2nd course, a relapse is predicted in patients with AML. Bone marrow sample preparation includes lysis of erythrocytes and staining of leukocytes with a panel of monoclonal antibodies.
EFFECT: method provides the possibility of increasing the efficiency of assessing MRD status in patients with AML, selecting a threshold value for establishing MRD-positive status, identifying the risk of relapse in patients with AML by determining the patient's MRD status by multicolor flow cytometry using gating and staining of leukocytes with a panel of monoclonal antibodies.
4 cl, 6 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELED DNA PROBES FOR DETERMINING THE EXPRESSION OF THE SOCS2, CD34, FAM30A, GPR56, DNMT3B, SPINK2 GENES, FOLLOWED BY DETERMINING THE LEVEL OF RELATIVE EXPRESSION RELATIVE TO THE ABL1 REFERENCE GENE, AMPLIFIED IN REAL-TIME PCR, USED TO PREDICT THE RISK OF EARLY RELAPSE IN CHILDREN WITH ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 2022 |
|
RU2783950C1 |
| METHOD FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA FROM PROGENITOR B-CELLS WITH REARRANGEMENTS IN THE KMT2A GENE IN CHILDREN OF THE FIRST YEAR OF LIFE | 2022 |
|
RU2797687C1 |
| METHOD OF UNDERLYING DISEASE EARLY RELAPSE DEVELOPMENT PREDICTION FOLLOWING AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL STEM HAEMOPOIETIC CELLS IN PATIENTS SUFFERING FROM HAEMOBLASTOSIS | 2007 |
|
RU2337712C1 |
| METHOD OF TREATING RECURRENT ACUTE MYELOID LEUKAEMIA FOLLOWING TRANSPLANTATION OF ALLOGENIC HAEMOPOIETIC STEM CELLS | 2013 |
|
RU2538799C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN THE PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIAS WITH ANTI-TUMOR PREPARATIONS DAUNORUBICIN AND CYTOSINE-ARABINOSIDE | 2019 |
|
RU2702657C1 |
| METHOD FOR DETECTION OF PRIMARY REFRACTORY FORM OF MULTIPLE MYELOMA AT THE DISEASE ONSET | 2020 |
|
RU2749612C1 |
| METHOD OF TREATING PATIENTS WITH PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF CENTRAL NERVOUS SYSTEM | 2024 |
|
RU2831407C1 |
| METHOD FOR DETERMINING HEMOSTASIS CRITERIA FOR PREDICTING UNFAVORABLE SEPSIS OUTCOME IN ACUTE MYELOBLASTOSIS CASES | 2006 |
|
RU2320996C1 |
| METHOD FOR DETERMINING MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY IN CHILDREN AND ADULTS WITH B-LINEAR ACUTE LYMPHOBLASTIC LEUKEMIA IN CONDITIONS OF CD19-DIRECTED IMMUNOTHERAPY | 2022 |
|
RU2818950C1 |
| METHOD OF DETERMINING EARLY LABORATORY MARKERS OF INFECTION GENERALISATION IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN CASE OF NEUTROPENIA | 2008 |
|
RU2391671C2 |
